HAV IgM ELISA Kit

Catalog No. ABIN997031

This Colorimetric ELISA kit is designed for the quantitative measurement of Hepatitis A Virus (HAV) HAV IgM.

Quick Overview for HAV IgM ELISA Kit (ABIN997031)

Target: HAV IgM (Anti-Hepatitis A Virus Antibody IgM (HAV IgM))

Reactivity: Hepatitis A Virus (HAV)

Detection Method: Colorimetric

Method Type: Competition ELISA

Application: ELISA

Sample Type: Serum

Product Details HAV IgM ELISA Kit

Purpose: The HAV IgM ELISA test is an enzyme-linked immunosorbent assay (ELISA) which is used for the qualitative determination of IgM-class antibodies to hepatitis A virus in human serum/plasma.

Analytical Method: Qualitative

Specificity: 100%

Sensitivity: 100%

Application Details

Sample Volume: 100 μL

Assay Time: 1 - 2 h

Plate: Pre-coated

Restrictions: For Research Use only

Handling

Storage: 4 °C

Expiry Date: 12-18 months

Target Details for HAV IgM

Target: HAV IgM (Anti-Hepatitis A Virus Antibody IgM (HAV IgM))

Alternative Name: HAV IgM

Target Type: Antibody

Background: Hepatitis A is a self-limited disease and chronic stage or other complications are rare. Infections occur early in life in areas where sanitation is poor and living conditions are crowded. With improved sanitation and hygiene, infections are delayed and consequently the number of persons susceptible to the disease increases. Because the disease is transmitted through the fecal-oral route in dense populated regions, an outbreak can arise from single contaminated source. The cause of hepatitis A is hepatitis A virus (HAV)-non enveloped positive strand RNA virus with a linear single strand genome, encoding for only one known serotype.

HAV has four major, structural polypeptides and it localizes exclusively in the cytoplasm of human hepatocytes. The infection with HAV induces strong immunological response and elevated levels first of IgM and then IgG are detectable within a few days after the onset of the symptoms. The presence of anti–HAV IgM is an important serological marker for early detection and observation of the clinical manifestation of the disease. Increasing levels of anti-HAV IgM are detectable about three weeks after exposure with highest titter after four to six weeks later. Within six months after infection IgM concentration declines to non-detectable levels.